hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06368934 id: KY2024-011 briefTitle: Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma overallStatus: NOT_YET_RECRUITING date: 2024-04-08 date: 2026-12 date: 2027-06 date: 2024-04-16 date: 2024-04-16 name: Huashan Hospital class: OTHER briefSummary: Glioblastoma is recognized as the most common and aggressive form of primary malignant brain tumor, with treatment options that are limited and prognosis that is extremely poor, showing median progression-free survival of 12 months and median overall survival of less than 18 months. Surgical resection plays a critical role in the treatment, with the extent of resection significantly impacting patient outcomes. Historical approaches to surgical resection have evolved, moving from radical strategies to more conservative ones that aim to preserve normal brain function while removing the tumor as completely as possible. Recent studies have suggested that increasing the extent of surgical resection, particularly along the T2 FLAIR border rather than the traditional T1-enhanced border, can significantly improve patient prognosis. There is, however, a lack of consensus on the optimal surgical approach, and the heterogeneity of tumors presents challenges in standardizing surgical strategies. Extended resection has been shown to prolong survival, and novel intraoperative molecular diagnostics have emerged to improve accuracy in tumor classification and prognosis. Building on these advancements, a multicenter, prospective, randomized controlled trial is proposed to evaluate the efficacy of sub-lobectomy in treating IDH wild-type/TERTp-mutant glioblastoma, aiming to improve evidence levels and establish standardized surgical practices for this devastating disease. conditions: Glioma conditions: Glioblastoma studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Type of study: randomized parallel controlled, open-label, multicenter clinical trial.
Randomization The control group and intervention group were equal in size. Following intraoperative pathological diagnosis, participants were randomly assigned using a centralized randomization system known as the Interactive Web Response System (IWRS). Stratification factors included preoperative age brackets of \[18-65\] and (65-80), gender (male or female), and tumor site in the frontal, temporal, parietal, and occipital lobes. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: This study employed a single-blind approach whereby the participants were unaware of the kind of surgical resection they were receiving. whoMasked: PARTICIPANT count: 326 type: ESTIMATED name: sub-lobectomy name: imaging total resection measure: Progression-free Survival measure: Overall Survival measure: Postoperative quality of life measure: Adverse effects measure: Cognitive function measure: Language function measure: Limb muscle strength sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hushan Hospital, Fudan University city: Shanghai state: Shanghai zip: 200040 country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06368921 id: VRT106-C01 briefTitle: A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors overallStatus: RECRUITING date: 2024-04 date: 2025-09 date: 2025-12 date: 2024-04-16 date: 2024-04-16 name: Guangzhou Virotech Pharmaceutical Co., Ltd. class: INDUSTRY briefSummary: To Evaluate the safety and tolerability of single and multiple intratumoral injections of recombinant oncolytic virus M1 (VRT106) in patients with locally advanced/metastatic solid tumors. conditions: Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: VRT106 measure: Evaluate the safety and tolerability of escalating doses of intratumoral injection of VRT106. measure: Characterize the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) levels. measure: Examine the biological distribution characteristics and shedding patterns of intratumoral injection of VRT106. measure: Assess the immunogenicity of intratumoral injection of VRT106. measure: Assess the anti-tumor effect of VRT106, including objective response rate (ORR) as efficacy indicators. measure: Assess the anti-tumor effect of VRT106, including disease control rate (DCR) as efficacy indicators. sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-sen University Cancer Center status: RECRUITING city: Guangzhou state: Guangdong country: China name: Hongyun Zhao role: CONTACT email: zhaohy@syscc.org.cn lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06368908 id: 6I/2023/3 briefTitle: Transcutaneous Functional Magnetic Muscle Stimulation in Critically Ill acronym: FMS_ICU overallStatus: RECRUITING date: 2023-12-08 date: 2024-10-30 date: 2024-12-30 date: 2024-04-16 date: 2024-04-16 name: General and Teaching Hospital Celje class: OTHER briefSummary: ICU-Acquired weakness (ICU-AW) is a significant complication of critical illness. ICU-AW is common in patients with sepsis, systemic inflammatory response, and mechanically ventilated. It is estimated that around 50% of patients recovering from the primary illness remain in intensive care with characteristic muscle weakness. This leads to dependence on mechanical ventilation, prolonging costly intensive care hospitalization. The myopathy causes persistent functional impairment, endangering patients long after hospital discharge.
The aim of the study is to investigate the effect of Functional Muscle Magnetic Stimulation (FMS) on the development of ICU-AW. conditions: Critical Illness Myopathy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: One of legs is randomised to be stimulated by trans-cutaneous functional magnetic stimulation (Arm 1), the other leg is control (Arm 2) primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Transcutaneous Functional Magnetic Muscle Stimulation measure: Measurement of Thickness of Thigh Muscles measure: Measurement of Thigh Circumference measure: Assessment of Muscle Strength and Communication Ability measure: Body composition measurement by bioimpedance- Extracellular water measure: Body composition measurement by bioimpedance- Intracellular water measure: Body composition measurement by bioimpedance- skeletal muscle mass sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: General Hospital Celje status: RECRUITING city: Celje zip: 300 country: Slovenia lat: 46.23092 lon: 15.26044 hasResults: False
nctId: NCT06368895 id: 2188 briefTitle: Fecal Microbiota Transplantation by Oral Capsules for Hepatic Encephalopathy Treatment overallStatus: RECRUITING date: 2021-04-07 date: 2025-06 date: 2025-06 date: 2024-04-16 date: 2024-04-16 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: This interventional study aims to evaluate the safety and efficacy of oral capsule fecal microbiota transplantation (FMT) for treating hepatic encephalopathy refractory to conventional rifaximin and lactulose therapy in patients with liver cirrhosis. Patients diagnosed with hepatic encephalopathy refractory to rifaximin and lactulose therapy will be randomized into three groups. While continuing conventional therapy, the first group receives FMT via colonoscopy and oral capsule administration, the second group receives only oral capsule administration, and the third group serves as a control, receiving only conventional therapy.
To evaluate metabolic modifications occurring after FMT and if they can be associated with clinical improvement. conditions: Hepatic Encephalopathy conditions: Dysbiosis studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Fecal microbiota transplantation delivery through colonoscopy name: Fecal microbiota transplantation delivery through oral capsules measure: Evaluation of safety of fecal microbiota transplantation by oral capsules in the treatment of cirrhotic patients with hepatic encephalopathy refractory to conventional therapy measure: Evaluation of efficacy of fecal microbiota transplantation by oral capsules in the treatment of cirrhotic patients with hepatic encephalopathy refractory to conventional therapy measure: Evaluation of changes in the gut microbiota composition following the fecal microbiota transplantation measure: Evaluation of changes in the systemic inflammatory following the fecal microbiota transplantation measure: Evaluation of changes in the intestinal inflammatory following the fecal microbiota transplantation measure: Comparison between protein metabolites concentration (ppm) in serum, urine and feces before and after microbiota transplantation measure: Comparison between lipid metabolites concentration (ppm) in serum, urine and feces before and after microbiota transplantation measure: Comparison between carbohydrates metabolites concentration (ppm) in serum, urine and feces before and after microbiota transplantation sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Policlinico Agostino Gemelli IRCCS status: RECRUITING city: Rome zip: 00168 country: Italy name: Francesca Ponziani, MD role: CONTACT phone: +390630156018 email: comitato.etico@policlinicogemelli.it lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06368882 id: Yongping _Chen briefTitle: Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT） overallStatus: RECRUITING date: 2024-01-01 date: 2028-12-31 date: 2028-12-31 date: 2024-04-16 date: 2024-04-16 name: First Affiliated Hospital of Wenzhou Medical University class: OTHER briefSummary: This is a prospective, multicenter, open-label, non-randomized controlled real-world study to explore the efficacy and safety and to accumulate more evidence-based medical data of an antiviral treatment programme for chronic viral hepatitis B with nonalcoholic fatty liver disease.
A total of 1500 patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease are divided into test group (1000 patients receiving PEG-IFNα-based antiviral therapy (combined NAs or Peg-IFNα monotherapy) and control group（500 patients receiving NAs monotherapy） according to their treatment intention. Laboratory and medical data from specified follow-up points are collected, and adverse events and drug combinations are recorded detailly.
The primary efficacy indicator is HBsAg clearance at 48 weeks of treatment, and the secondary indicators included: (1) HBsAg clearance at 96 weeks of treatment, (2) Cumulative HBsAg clearance at week 24、120、144、168、192、216 and 240; (3) The improvement of liver function level(ALT, AST, TBIL, etc.), blood lipid (TC, TG, LDL-C, HDL-C, etc.), fasting blood glucose, insulin resistance index (HOMA-IR), controlled attenuation parameter, body mass index , liver stiffness measurement, liver histological fibrosis, FIB-4 index from baseline; (4)Incidence of liver cirrhosis and hepatocellular carcinoma during follow-up.
The security assessment includes adverse events, vital signs, and imaging. conditions: Nonalcoholic Fatty Liver Disease conditions: Chronic Hepatitis b studyType: INTERVENTIONAL phases: PHASE4 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 1500 type: ESTIMATED name: Peg-Interferon α measure: HBsAg clearance measure: HBsAg clearance at 96 weeks measure: Cumulative HBsAg clearance rate measure: Liver Function Tests measure: The incidence of liver cirrhosis and liver cancer sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Ningbo No.2 Hospital status: RECRUITING city: Ningbo country: China name: Hongshan Li role: CONTACT phone: 13738865021 lat: 29.87819 lon: 121.54945 facility: Ruian People's Hospital status: RECRUITING city: Rui'an country: China name: Liang Hong role: CONTACT phone: 13958805550 facility: The Second Affiliated Hospital of Wenzhou Medical University status: RECRUITING city: Wenzhou country: China name: Chenwei Pan role: CONTACT phone: 13587655994 lat: 27.99942 lon: 120.66682 facility: Wenzhou People's Hospital status: RECRUITING city: Wenzhou country: China name: Ran Ding role: CONTACT phone: 18057788513 lat: 27.99942 lon: 120.66682 facility: Yueqing People's Hospital status: RECRUITING city: Yueqing country: China name: Hui Zhao role: CONTACT phone: 13968713322 hasResults: False
nctId: NCT06368869 id: #1/2022 briefTitle: The Effect of Different Types of Resin Cements on the Color Stability of Two Different Types of Ceramic Veneers overallStatus: COMPLETED date: 2023-01-10 date: 2024-01-20 date: 2024-01-20 date: 2024-04-16 date: 2024-04-16 name: amr elshimy class: OTHER briefSummary: Aim of the study was to evaluate the color stability of lithium disilicate ceramic veneers and zirconia reinforced lithium silicate ceramic veneers by using two different types of resin cements including light cured and dual cured cements. conditions: Color; Change Teeth, Posteruptive studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 44 type: ACTUAL name: Livento press veneers luted with dual cured resin cement name: Livento press veneers luted with light cured resin cement name: Celtra duo veneers luted with dual cured resin cement name: Celtra duo veneers luted with light cured resin cement measure: Color stability assessment sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Faculty of Dentistry, Alexandria University city: Alexandria country: Egypt lat: 31.21564 lon: 29.95527 hasResults: False
nctId: NCT06368856 id: 20CH024 id: 2020-006105-30 type: EUDRACT_NUMBER briefTitle: Pharmacology of Mupirocin in Nasal Application in Healthy Volunteers: Monocentric Study acronym: MUPIPHARM overallStatus: RECRUITING date: 2024-02-29 date: 2024-11 date: 2025-03 date: 2024-04-16 date: 2024-04-16 name: Centre Hospitalier Universitaire de Saint Etienne class: OTHER briefSummary: Mupirocin is an old antibiotic used topically since the 1970s. Initially used in the treatment of skin infections for its antistaphylococcal action, it is now part of the decolonization strategy for Staphylococcus aureus (SA) carriage, in association with chlorhexidine. This decolonization strategy has been recommended in France for preoperative cardiac surgery in nasal SA carriers since 2013 by the French Hospital Hygiene Society, and recommended for cardiac and orthopedic surgery in SA carriers by the World Health Organization (WHO) since 2016. This strategy includes nasal decolonization using mupirocin ointment nasally (2 to 3 applications/day), a daily shower with chlorhexidine soap and + /- mouthwashes all over 5 days, often pre-operatively.
It therefore seems essential to conduct a pharmacokinetic study of this molecule, in order to eventually offer patients the regimen with the administration methods offering the best characteristics in terms of dosage and efficacy. conditions: Healthy conditions: Staphylococcus Aureus Infection studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Single-center, randomized, open-label pharmacokinetic study of mupirocin in 40 healthy subjects with 2 randomization :
* second randomization - repeated doses part: 50mg mupirocin twice a day or 50 mg 3 times a day 500mg mupirocin twice a day or 500mg mupirocin 3 times a day primaryPurpose: OTHER masking: NONE count: 40 type: ESTIMATED name: Mupirocin (50 mg) name: Mupirocin (500 mg) name: blood samples after Single dose part name: nasal swab after Single dose part name: Collection of urine after Single dose part name: nasal swab during Repeated dose part name: Collection of urine during Repeated dose part name: nasal swab after Repeated dose part measure: plasma concentrations of mupirocin measure: plasma concentrations of mupirocin measure: plasma concentrations of mupirocin measure: intranasal concentrations of mupirocin measure: intranasal concentrations of mupirocin measure: intranasal concentrations of mupirocin measure: intranasal concentrations of mupirocin measure: intranasal concentrations of mupirocin measure: intranasal concentrations of mupirocin measure: presence of Staphylococcus aureus measure: presence of Staphylococcus aureus measure: presence of Staphylococcus aureus measure: presence of Staphylococcus aureus measure: urinary concentrations of monic acid measure: urinary concentrations of monic acid measure: urinary concentrations of monic acid measure: urinary concentrations of monic acid sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU de SAINT-ETIENNE status: RECRUITING city: Saint-Étienne country: France name: Kasra AZARNOUSH, MD PhD role: PRINCIPAL_INVESTIGATOR name: Elisabeth BOTELHO-NEVERS, MD PhD role: SUB_INVESTIGATOR name: Anne CARRICAJO, MD role: SUB_INVESTIGATOR name: Philippe BERTHELOT, MD PhD role: SUB_INVESTIGATOR lat: 45.43389 lon: 4.39 hasResults: False
nctId: NCT06368843 id: Ketamine for POST briefTitle: the Impact of Ketamine Gargling on the Incidence of Post Intubation Sore Throat overallStatus: NOT_YET_RECRUITING date: 2024-04-25 date: 2024-08-15 date: 2024-09-20 date: 2024-04-16 date: 2024-04-16 name: Al-Azhar University class: OTHER briefSummary: Tracheal intubation often causes trauma to the airway mucosa, leading to postoperative sore throat (POST), which has been reported to occur in 21-65% of cases. While considered a minor complication, POST can contribute to postoperative discomfort and patient dissatisfaction. conditions: Postoperative Sore Throat studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 80 type: ESTIMATED name: Gargle with ketamine measure: Sore throat measure: Cough measure: Hoarseness of voice sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Ministry of Health city: Baghdad state: Thi-Qar zip: 00964 country: Iraq lat: 33.34058 lon: 44.40088 hasResults: False
nctId: NCT06368830 id: 2024-0337 id: A534100 type: OTHER domain: UW Madison id: Protocol Version 3/4/24 type: OTHER domain: UW Madison briefTitle: Oral and Swallowing Function in Older Adults overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2026-05 date: 2024-04-16 date: 2024-04-16 name: University of Wisconsin, Madison class: OTHER briefSummary: The purpose of this study is to learn about oral and swallowing function in older adults presenting to the emergency department. The hypothesis is that older adults often have problems with oral and swallowing function and these problems relate to other conditions. Study activities are done during the emergency department visit and include providing saliva samples, completing a bedside water swallow test, completing oral function assessments, completing respiratory function tests, and answering survey questions. conditions: Oropharyngeal Dysphagia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: 3-ounce water swallow test name: Kayser-Jones Brief Oral Health Status Examination (BOHSE) name: Tongue pressure name: Test of Masticating and Swallowing Solids (TOMASS) name: Respiratory function tests measure: Positive oropharyngeal dysphagia screen prevalence measure: Mean brief oral health status examination (BOHSE) score measure: Oral dryness prevalence measure: Decreased tongue pressure prevalence measure: Decreased masticatory function prevalence measure: pH of saliva sample measure: Extensional viscosity of saliva sample measure: Salivary Substance P Concentration measure: Oral microbiome measure: Cell barrier function measure: Protein composition measure: Gene expression measure: Immunofluorescent staining measure: Immune cell trafficking sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT hasResults: False
nctId: NCT06368817 id: ACNS2321 briefTitle: Chemotherapy Followed by Response-Based Reduced Radiation Therapy for Patients With Central Nervous System Germinomas overallStatus: NOT_YET_RECRUITING date: 2024-05-04 date: 2033-11-04 date: 2033-11-04 date: 2024-04-16 date: 2024-04-16 name: Children's Oncology Group class: NETWORK briefSummary: A phase II trial that is attempting to build upon the excellent results of ACNS1123 stratum 2 by reducing the Radiotherapy (RT) dose for patients in a Complete Response (CR) after chemotherapy. The trial will be testing a further reduction in the whole ventricular irradiation (WVI) dose. Additionally, patients with metastatic disease and basal ganglia and thalamic germinoma will be included, and they will be treated with craniospinal irradiation (CSI) or whole brain irradiation (WBI) respectively. conditions: Intracranial Germ Cell Tumor conditions: Childhood Central Nervous System Germinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 240 type: ESTIMATED name: 3-Dimensional Conformal Radiation Therapy name: Carboplatin name: Etoposide name: Intensity-Modulated Radiation Therapy measure: Event-free survival (EFS) measure: Estimate the EFS distribution for eligible and evaluable patients in Stratum 2 measure: To estimate the EFS distribution for eligible and evaluable patients in Stratum 3 measure: Overall Survival (OS) measure: Determine the impact of tumor location, treatment regimen and treatment modalities on the long-term neuroendocrine function for patients with CNS germinomas. measure: Prospectively evaluate processing speed of children and young adults with CNS germinoma through the Children's Oncology Group (COG) Standardized assessment battery. measure: EFS distribution for eligible and evaluable patients in Stratum 4 and Stratum 5. measure: EFS distribution for eligible and evaluable patients in Stratum 6 and Stratum 7. measure: prospectively collect blood, cerebrospinal fluid, and tumor tissue at diagnosis and second-look surgery (if feasible) for future biology studies. measure: Incidence of cerebral vascular events (stroke or transient ischemic attacks) of children and young adults with CNS germinoma through the COG Standardized assessment battery: Patient-reported outcome measures measure: Incidence of cerebral vascular events (stroke or transient ischemic attacks) of children and young adults with CNS germinoma through the COG Standardized assessment battery: Health-reported quality of life sex: ALL minimumAge: 3 Years maximumAge: 30 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06368791 id: 30001479 briefTitle: Anti-Stress Intervention Among Physicians Study acronym: ASIP overallStatus: RECRUITING date: 2024-04-15 date: 2024-06-30 date: 2024-10-30 date: 2024-04-16 date: 2024-04-26 name: Charite University, Berlin, Germany class: OTHER briefSummary: Medical practice often comes with high stress. Stress negatively affects our health and well-being and is linked to doctors making mistakes, some of which can be deadly.
The effectiveness of these interventions is being examined in a series of N-of-1 trials. Each participant can choose between the interventions. After being randomly allocated to an individual sequence of one-week intervention and control phases, the study begins. Participants record their stress levels daily over the four-week study period. The intervention is only performed in the intervention phases. Upon completing the study, the stress levels during the intervention phases are compared to those in the control phases. Each participant will receive an individual analysis based on the collected data. In addition, the investigators will estimate the effects at the population level.